Business
Like many product-focused companies, we are exposed to market risks from changes in commodity or other raw material prices.
MEDIFAST INC: Revenue declined 36% to $386M from $602M. Net income turned into a $18.67M loss from $2.091M of profit. Free cash flow declined 92.7% to $1.249M from $17.02M. Operating margin contracted 416 bps to -3.68%. MEDIFAST INC's annual comparison also shows stock compensation grew faster than revenue.
The read at a glance✓ Audited against SEC data
- Growth — Revenue declined 36% to $386M from $602MWatch
- Profitability — Net income turned into a $18.67M loss from $2.091M of profitWatch
- Cash flow — Free cash flow declined 92.7% to $1.249M from $17.02MWatch
- Margins — Operating margin contracted 416 bps to -3.68%Watch
- Accounting — No overriding statistical warningNote
- Insiders — 3 purchases and 0 salesOK
Where the revenue comes from
Fiscal 2025, as MEDIFAST INC reports it. History and quarterly detail are in the app.
- Optavia$385.8M
Leadership changes
From MEDIFAST INC's own filings, the day they're filed.
- Jason L. Groves · Chief Legal Officer · departureeff. 2026-05-29
Latest filings
- 8-K · Company announcement2026-08-03
- 10-Q · Quarterly report2026-08-03
- 8-K · Company announcement2026-07-17
- 8-K · Company announcement2026-06-01
- 8-K · Company announcement2026-05-26
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about MEDIFAST INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.